Chlorogenic acid: a review on its mechanisms of anti-inflammation, disease treatment, and related delivery systems

1Chlorogenic acid (CGA), alternatively termed as coffee tannic acid and coffee ellagic acid, is a water-soluble phenolic acid synthesized by plants during aerobic respiration. This acid arises from the esterification of caffeic acid and quinic acid, boasting a molecular architecture characterized by three labile groups: ester bonds, unsaturated double bonds, and dibasic phenols. Key functional groups underpinning its bioactivity encompass hydroxyl, carboxyl, and o-diphenol hydroxyl groups. Empirical research has underscored the efficacy of chlorogenic acid in ameliorating inflammatory ailments, attributing this to its multifaceted targeting of inflammatory pathways and its diminished propensity for drug resistance. Specifically, chlorogenic acid can attenuate cardiac and cerebral afflictions triggered by inflammation and oxidative stress, conferring cardiovascular and cerebrovascular protective effects. Concurrently, research has illuminated chlorogenic acid’s potential in enhancing metabolic parameters in hepatic and cardiac contexts, serving as a bulwark against obesity, cardiovascular maladies, and diabetes. In the realms of obesity and diabetes, chlorogenic acid has been identified to impede sugar absorption by human intestinal epithelial cells (Caco-2) via the modulation of Glut gene expression. Additionally, it augments postprandial glycemic regulation, glucagon-like peptide-1 (GLP-1) response, and insulin sensitivity in normative populations. Given its distinctive anti-inflammatory attributes and pronounced benefits concerning cardiovascular, cerebrovascular, and diabetic conditions, chlorogenic acid is gaining traction in pharmaceutical and biomedical research arenas.

2However, there are inherent challenges with chlorogenic acid, primarily its chemical instability, limited lipid solubility, suboptimal bioavailability, and vulnerability to esterase-mediated degradation. Serendipitously, chlorogenic acid undergoes isomerization during extraction, yielding more stable forms in nature, which effectively addresses some of these limitations. This isomerization engenders six principal isomers, notably cryptochlorogenic acid (4-caffeoylquinic acid), neochlorogenic acid (5-caffeoylquinic acid), and a series of isochlorogenic acids, as depicted in Figure 1. The isomerized chlorogenic acid retains its biologically active profile, exhibiting potent anti-inflammatory and antioxidant capacities. To further refine the bioavailability of chlorogenic acid and circumvent its degradation, myriad packaging and delivery modalities have been innovated, such as liposomes, micelles, and nanoparticles, addressing the twin challenges of chemical instability and suboptimal bioavailability, thus broadening the horizon for its clinical deployment.

3In this manuscript, a meticulous exploration of chlorogenic acid, its derivational isomers, and their associated biological mechanisms is undertaken. Furthermore, in anticipation of prospective practical challenges, drug delivery systems optimized for chlorogenic acid are elucidated.

4At the molecular intersection of inflammatory pathways, chlorogenic acid predominantly impedes the synthesis and secretion of inflammatory mediators such as TNF-α, NO, COX-2, and PGE2. These mediators interplay in a complex manner, instrumental in the inception and progression of inflammation.

5Under conditions of excessive immunological perturbation, a protracted inflammatory response can be initiated, thereby inflicting collateral damage upon native cellular structures and instigating pathophysiological transformations. Notably, isochlorogenic acid has been identified to markedly attenuate pro-inflammatory cytokine levels, encompassing TNF-α, IL-6, IL-8, and IFN-γ, while concurrently enhancing anti-inflammatory cytokine concentrations, such as IL-10, ultimately mitigating inflammation in chicken fallopian tubes. In a landmark study, elevated concentrations of chlorogenic acid were found to shift macrophages away from classical inflammatory pathways, favoring their differentiation mediated by Coxsackie virus B3 (CVB3) towards the M2 pathway. This shift culminated in reduced synthesis of pro-inflammatory cytokines like TNF-α, IL-6, and IL-8. Analogously, chlorogenic acid demonstrated efficacy in curbing the proliferation of hemolytic streptococcus, attenuating the production of IL-6, TNF-α, and IL-1β, thus effectively quelling the inflammatory cascade in hemolytic streptococcus-infected mice. Subsequent animal studies have emphasized the robust antioxidant potential of chlorogenic acid, highlighting its ability to curtail serum TNF-α levels, neutralize oxygen radicals, enhance superoxide dismutase (SOD) concentrations, and foster the repair of collagen fibers, making it a promising candidate for oral ulcer therapy in murine models. Furthermore, chlorogenic acid evidenced potential in diminishing the expression of pro-inflammatory markers like TNF-α and IL-6, thus counteracting the inflammatory sequelae in diabetic rodents induced by streptozotocin. Pertinently, reactive oxygen species (ROS) and reactive nitrogen species (RNS) have been earmarked as viable therapeutic agents for type 1 diabetes-induced inflammation. Additionally, research delineated the efficacy of chlorogenic acid in abating intestinal inflammation, fortifying the intestinal barrier, and ameliorating glucose metabolism dysregulation in type 2 diabetic rodents.

6Inducible Nitric Oxide Synthase (iNOS), predominantly located within macrophages and leukocytes, facilitates NO synthesis, integral to the inflammatory cascade. In the milieu of inflammation, NO serves as an amplifier. The genesis and activation of iNOS in tissues by pro-inflammatory cytokines catalyze NO synthesis. Excessive NO accumulation exacerbates inflammatory pathways, intensifying the response. Chlorogenic acid has been observed to diminish NO and IL-6 concentrations, mollify LPS-induced inflammatory onslaughts in murine peritoneal macrophages (RAW264.7), curtail peroxidase (MPO) expression, and elevate tissue superoxide dismutase (SOD) levels, thus showcasing promise as a potential therapeutic agent for ulcerative colitis in mice. In vitro macrophage experiments post-LPS induction revealed that both chlorogenic acid and cryptochlorogenic acid notably suppressed iNOS expression and NO synthesis. Compounds such as chlorogenic acid, cryptochlorogenic acid, and 5-caffeoylquinic acid manifested inhibitory effects on NO secretion from LPS-stimulated murine macrophages. In vivo experiments further highlighted the pronounced anti-inflammatory prowess of chlorogenic acid. Specifically, isochlorogenic acid C substantially reduced NO and PGE2 concentrations in the serum of mice subjected to carrageenan exposure, while the antioxidant properties of isochlorogenic acid A and isochlorogenic acid C neutralized free radical-induced damage and subdued inflammatory pathways in murine feet. In a parallel vein, chlorogenic acid effectively stymied the acute inflammatory repercussions induced by xylene, leading to significant reductions in ear edema.

7Prostaglandin E2 (PGE2) plays a pivotal role in amplifying inflammatory reactions and augmenting nociceptive sensitivity. Concurrently, COX-2 is instrumental in enhancing PGE2 synthesis during inflammation. In instances of pronounced inflammatory perturbations, pro-inflammatory cytokines can instigate elevated COX-2 expression. This elevation, in turn, accelerates the metabolism of arachidonic acid (AA) to yield heightened levels of PGE2, perpetuating a positive feedback loop that intensifies the inflammatory cascade. Chlorogenic acid demonstrates its anti-inflammatory prowess by attenuating the M1 macrophage-mediated inflammatory response, achieved through the downregulation of genes pivotal to polarization, encompassing COX-2, IL-6, and TNF-α. As a corollary, the synthesis of PGE2 witnesses a concomitant reduction. Furthermore, chlorogenic acid has exhibited efficacy in suppressing COX-2 expression in the context of acute pulmonary tissue injury in murine models.

8The NF-κB complex primarily consists of two heterodimeric subunits, P50 and P65. In its quiescent state, NF-κB is sequestered in the cytoplasm, bound to IκB (an inhibitor of NF-κB). Upon activation, IκB undergoes phosphorylation and ubiquitination, facilitating the nuclear translocation of NF-κB to bind target genes, orchestrating the transcriptional modulation of the inflammatory cascade. Chlorogenic acid’s capacity to mitigate inflammation via impeding this signaling conduit has been substantiated across diverse cellular and tissue frameworks. For instance, investigations have discerned that chlorogenic acid attenuates the inflammatory milieu in rheumatoid arthritis by suppressing NF-κB expression and its consequent DNA-binding activity, culminating in the inhibition of downstream TNF-α secretion. Several empirical assessments corroborate that chlorogenic acid, in a dose-responsive manner, downregulates inflammatory mediators including IL-6, TNF-α, IL-1β, and TLR2 by hindering the phosphorylation of NF-κB pathway proteins, positioning chlorogenic acid as a prospective therapeutic agent for dairy mastitis. Notably, one research endeavor illuminated chlorogenic acid’s potential to counteract the P65 upregulation, thus dampening the inflammatory perturbations in Caco-2 cells incited by interferon-gamma (IFNγ) and myristate (PMA). Moreover, in the context of LPS-induced retinal inflammation, chlorogenic acid curbed diabetic retinopathy by diminishing p65 phosphorylation and curtailing the release of IL-6 and TNF-α.

9Further delving into the mechanistic intricacies, there’s burgeoning evidence elucidating the upstream regulatory axes through which chlorogenic acid navigates the NF-κB signaling trajectory. Pioneering studies have demystified chlorogenic acid’s competency in negating the TLR4/NF-κB signaling cascade, leading to a conspicuous reduction in TLR4, MyD88, and NF-κB expression levels, thereby ameliorating oxidative impairments in small intestinal tissue and refining the inflammatory demeanor of septic rat epithelial cells. The TOLL receptor 4 (TLR4)/MyD88 axis might further invigorate IKK, engendering IκB degradation and triggering NF-κB activation, thereby catalyzing the inflammatory cascade. Chlorogenic acid, by moderating the TLR4 pathway, can stymie the transcriptional vigor of NF-κB, offering a dual benefit of thwarting macrophage-derived foam cell proliferation and fostering their apoptosis, bestowing considerable cardiorenal protective attributes.

10In synthesis, chlorogenic acid adeptly impedes the NF-κB signaling cascade’s activation, primarily by stalling the phosphorylation events associated with IKK, IκB, and P65. Concurrently, it also suppresses the upstream signaling pathways, notably the TOLL receptor4 (TLR4)/MyD88 nexus, thereby manifesting robust anti-inflammatory attributes.

11MAPK represents a distinct category of serine/threonine kinases. The intricate MAPK signaling cascade encompasses three predominant pathways: ERK, P38, and JNK, each capable of transducing diverse signals to the nucleus, subsequently binding to specific proteins to initiate and amplify inflammatory responses.

12Chlorogenic acid has been evidenced to quell the phosphorylation of the trio of kinases–ERK1/2, P38, and JNK, subsequently mitigating dextrose sulfate (DSS)-provoked intestinal inflammation and oxidative stress. In the context of LPS-mediated cardiomyocyte inflammation in mice, chlorogenic acid has been shown to attenuate myocardial inflammation, chiefly by obviating upstream MEK phosphorylation and suppressing ERK expression. Moreover, chlorogenic acid conferred protection against myocardial ischemia-reperfusion-induced inflammatory lesions and oxidative distress in rats, achieved by thwarting the activation of the MEK/ERK signaling axis and diminishing the myocardial infarct dimensions. Furthermore, chlorogenic acid inhibited P38 phosphorylation, culminating in a diminished release of downstream pro-inflammatory mediators IL-6 and TNF-α, as evidenced in a model involving transforming growth factor (TGF)-β1-induced hepatic stellate cell (HSC) activation. By constraining p38 phosphorylation, chlorogenic acid fostered autophagic processes in Salmonella typhi (ST)-infected mouse intestinal epithelial cells, leading to a reduction in mouse mortality. In a model of cardiac injury using TNF-α-induced human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), chlorogenic acid, upon pre-administration, counteracted TNF-α-mediated cellular detriment via a mechanism potentially linked to the inhibition of the JNK pathway, and by extension, the overarching MAPK signaling conduit.

13Nrf2, a nuclear transcription factor E2-related factor, plays an instrumental role in combating oxidative stress and dampening inflammatory cascades. Chlorogenic acid is renowned for its anti-inflammatory and antioxidant prowess, largely attributed to its capacity to activate the Nrf2 signaling paradigm. Once actuated, Nrf2 translocates to the nucleus, binding to its target genes and orchestrating the transcription of a cadre of affiliated proteins, including hemoglobin oxidase-1 (HO-1), pro-quinone oxidoreductase-1 (NQO-1), and γ-glutamylcysteine synthetase (γ-GCS), which collectively render anti-inflammatory and antioxidant effects.

14Research indicates that chlorogenic acid facilitates the liberation of Nrf2 from its binding partner keap1, culminating in Nrf2 activation and concomitant upregulation of HO-1 and NQO-1. A seminal study posited that chlorogenic acid mitigated acetaminophen (APAP)-induced inflammatory perturbations in liver tissues, a modulation attributable to Nrf2 activation; intriguingly, this anti-inflammatory efficacy of chlorogenic acid was notably compromised in the absence of Nrf2. In a rat model simulating sepsis, chlorogenic acid heightened Nrf2 protein expression, resulting in the augmented release of HO-1 and NQO1, thereby curbing macrophage activity and ameliorating both inflammation and oxidative stress-induced pulmonary tissue damage. Moreover, chlorogenic acid displayed a remedial effect against LPS-triggered acute kidney injury by abrogating inflammatory responses and systemic oxidative stress, a mechanism presumably linked to the activation of the Nrf2 pathway, bolstering Nrf2 nuclear translocation and subsequent protein expression of downstream targets HO-1 and NQO1. Studies have also demonstrated that chlorogenic acid counteracts type 1 diabetic retinopathy (DR) manifestations by fortifying Nrf2 activation, obstructing TNF-α-mediated retinal endothelial-mesenchymal (EndoMT) and epithelial-mesenchymal (EMT) transitions, and mitigating oxidative damage. Furthermore, chlorogenic acid manifests a robust protective effect against Doxorubicin (DOX)-mediated cardiotoxicity in rats; this cardioprotection appears to be hinged on chlorogenic acid’s ability to suppress apoptotic marker caspase-3 expression and tyrosine, whilst enhancing Nrf2 and Ho-1 expression in the cardiac milieu.

15Chlorogenic acid, recognized as a pivotal natural compound, possesses a diverse array of pharmacological properties. Particularly noteworthy are its anti-inflammatory and antioxidant capabilities, which render it efficacious in the prophylaxis and therapeutic management of cardiovascular and cerebrovascular maladies.

16Empirical research underscores that chlorogenic acid mitigates the severity of ventricular myocardial infarction and augments cardiac functionality by attenuating inflammatory mediators and enhancing the activity of antioxidant enzymes, thereby serving as an instrumental player in forestalling myocardial infarction. Additionally, chlorogenic acid presents a prophylactic approach against thrombotic events following valve replacement in advanced heart valvular disorders, attributable to its anticoagulant properties and its role in fostering endothelial cell proliferation.

17Concomitantly, its cardioprotective attributes are further elucidated through modulating pertinent signaling pathways. Chlorogenic acid has been documented to counteract doxorubicin-triggered cardiotoxicity by orchestrating the Nrf2/HO-1 signaling cascade, thus manifesting profound cardioprotective ramifications. Furthermore, chlorogenic acid impedes the progression of cardiac fibroblasts (CFs), a phenomenon potentially steered by the TGF-βl/Smads signaling pathway.

18Chlorogenic acid offers protection to hippocampal neurons, primarily by negating mitochondrial aberrations and calcium overload, positioning it as a promising therapeutic candidate for epilepsy. Apoptotic pathways largely underpin neuronal impairment following cerebral ischemia-reperfusion (I/R) insult. In this context, chlorogenic acid markedly diminishes the expression of the NF-κB protein in hippocampal neurons of I/R-challenged rats, unveiling a novel therapeutic target for ischemic cerebrovascular accidents. Chlorogenic acid, when administered prophylactically, ameliorates cognitive impairments, unveiling neuroprotective attributes in transient forebrain ischemia (TFI) scenarios. This neuroprotection appears to correlate with an upregulation in SOD2 expression facilitated by chlorogenic acid. Concurrently, chlorogenic acid elevates antioxidant enzyme expression and anti-inflammatory cytokine levels, while diminishing oxidative stress markers and pro-inflammatory cytokines. Additionally, the compound bolsters SOD activity, elevates GSH concentrations, curtails ROS and LDH production, reduces MDA accumulation, and ameliorates cerebral ischemia-reperfusion (CI/R) injury sequels.

19In streptozotocin (STZ)-elicited diabetic rat prototypes, chlorogenic acid demonstrates therapeutic potential against type 1 diabetes-mediated inflammation, achieved through the downregulation of IL-6 and tumor necrosis factor in rat circulatory systems. Beyond this, chlorogenic acid wields significance in addressing diabetes-associated complications. Diabetic hyperglycemic states activate the NF-κB signaling pathway in neuronal structures, culminating in diabetic encephalopathy and subsequent cognitive decline (F et al., 2023). Chlorogenic acid ameliorates such cognitive deficits, a process conceivably attributed to its inhibitory action on NF-κB and IL-6 within frontal brain structures (F et al., 2023). Excessive glucose levels can instigate endothelial cell dysfunction. In a diabetic murine model with aortic endothelium-dependent relaxation under high glucose challenge, chlorogenic acid mitigates endothelial anomalies through the activation of the Nrf2 antioxidant pathway.

20In the burgeoning realm of chlorogenic acid research, clinical trials have illuminated promising results. Observational studies discern that chlorogenic acid precipitates a notable decrement in C-reactive protein (CRP) and IL-6 concentrations in subjects, augments cardiometabolic indices, and exhibits a commendable therapeutic efficacy in cardiovascular disorders. Furthermore, chlorogenic acid has been credited with attenuating body mass in diabetic cohorts via the amplification of intestinal bifidobacterial populations, and has manifested improvement in endothelial dynamics among stage 1 hypertensive patients. In summation, the paramountcy of chlorogenic acid in disease prophylaxis and management cannot be overstated, and ensuing research endeavors will expound upon clinical trials to discern the intricate mechanisms mediated by chlorogenic acid.

21While chlorogenic acid holds promise as a therapeutic agent in mitigating inflammatory disorders, cardiovascular and cerebrovascular maladies, and diabetes, the intrinsic limitations posed by its molecular configuration, marked by unstable moieties, fickle chemical traits, suboptimal lipid solubility, and diminished bioavailability in vivo, constrain its biomedical potential. Albeit various chlorogenic acid isomers exhibit salient advantages over their native counterpart, they occasionally betray certain toxicological concerns and adverse manifestations. Consequently, a panoply of chlorogenic acid encapsulation and delivery stratagems have been envisaged, encompassing liposomes, micelles, and nanoparticles, among others.

22Endowed with a molecular architecture chiefly composed of phospholipids and fatty acids, and reminiscent of cellular membranes, liposomes have been canonized for their innate biocompatibility and biodegradability. These entities, comprising amphiphilic molecules orchestrating into bilayered vesicles, emerge as exemplary conduits for an assortment of molecular species with varying polarities (E et al., 2021). A salient advantage of liposomes resides in their ability to stabilize active agents, surmount barriers thwarting cellular drug uptake, extend the retention span of therapeutics within target cells, and thereby potentiate therapeutic outcomes. An in vivo evaluation heralded a 1.29-fold enhancement in the bioavailability of a chlorogenic acid extract upon its encapsulation within soy phosphatidylcholine and cholesterol liposomes (maintaining a liposome-to-chlorogenic acid ratio of 6:1), suggesting liposomal encapsulation as a viable strategy for bolstering compound bioavailability. In the milieu of simulated in vitro gastrointestinal digestion (GID), a 40% decrement in chlorogenic acid content has been reported. However, juxtaposed against this observation, the chlorogenic acid content ensconced within liposomes remains predominantly conserved throughout gastrointestinal digestive episodes, forestalling its degradation or morphological transformations.

23Distinguished from liposomes in their architectural nuances, micelles present themselves as closed lipid monolayers, manifesting with polar head groups on the exterior and hydrophobic tails sequestered internally. This unique configuration augments the solubility of an array of hydrophobic pharmaceuticals. Furthermore, micelles amplify the permeability of drugs and enhance their effective concentration in situ, thereby augmenting the bioavailability of the encapsulated compound. In a seminal study, chlorogenic acid was encapsulated onto poly (D, L-lactide-co-glycolide) (PLGA) and subsequently adorned with polyvinylpyrrolidone (PV) to fabricate nano-micelles. Subsequent in vivo mouse assays and in vitro assessments divulged that these nanomicelles not only elongate the tissue residence time but also modulate the sustained release of chlorogenic acid, underpinning their commendable biocompatibility. In a different vein, micelles have found applicability in extraction protocols. Evidence suggests that the yield from ultrasonic-assisted micellar-mediated extraction (UAMME) trumps that from conventional aqueous extractions, whilst preserving the biological fidelity of the extract.

24Nanoparticles amplify the stability of bioactive moieties, facilitating their traverse across cellular membranes and biological impediments, thereby ensuring a controlled release within the target cellular milieu. One pivotal investigation showcased that bovine serum albumin (BSA)-facilitated chlorogenic acid silver nanoparticles (AgNPs-CGA-BSA) exude substantial antioxidant and anti-neoplastic properties across in vivo and in vitro matrices. Moreover, indices such as reduced glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT) exhibited amplified activities in DLA cells and murine serum post AgNPs-CGA-BSA treatment, positing a prospective therapeutic avenue for T-cell lymphoma. Additionally, chlorogenic acid-encased mesoporous silica entities, tailored with hexahistidine peptide sequences, demonstrated a potential to attenuate metal-induced dermal inflammation in mice via robust nickel chelation. Such modifications resulted in a formidable 63.22% release of chlorogenic acid at the 10-h mark.

25In contemporary years, the exploration into chlorogenic acid’s anti-inflammatory mechanisms has burgeoned, with revelations permeating diverse scientific domains. At the molecular crossroads of inflammation, chlorogenic acid predominantly forestalls the synthesis and subsequent discharge of bioactive molecules such as TNF-α, NO, COX-2, and PGE2. Notably, it curtails the release of TNF-α and interleukin derivatives by thwarting the activation of both macrophages and monocytes. Analogously, it counteracts inflammation propagation by inhibiting nitric oxide synthesis. In circumstances where heightened inflammatory reactions elevate COX-2 expression, chlorogenic acid intervenes by attenuating PGE2 synthesis, thereby obviating inflammatory-induced tissue detriment. On the signalling axis, chlorogenic acid orchestrates a triad of regulatory modalities that modulate inflammatory pathway constituents. This, in turn, precludes exacerbations incited by primordial inflammatory agents or exogenous triggers, ensuring inflammation’s containment and resolution.

26Chlorogenic acid exerts its anti-inflammatory prowess through a two-pronged molecular strategy. Primarily, it impedes the activation of NF-κB, p65, IκB, and IKK, ensuring that NF-κB is barred from nuclear translocation and subsequent target gene binding, thereby manifesting its anti-inflammatory attributes. Subsequently, chlorogenic acid stymies the phosphorylation of ERK1/2, JNK, and P38, effectively curtailing the MAPK signaling pathway. Furthermore, by fostering the expression of HO-1 and NOQ-1 and concurrently suppressing the secretion of pivotal inflammatory mediators such as IL-1β, IL-6, and IL-8 from macrophages, chlorogenic acid achieves this via the activation of Nrf2. The encapsulated anti-inflammatory mechanism of chlorogenic acid is depicted in Figure 2.

27Additionally, chlorogenic acid holds promise in mitigating inflammatory disorders, cardiovascular anomalies, cerebrovascular conditions, diabetes, and an array of other ailments. This is achieved predominantly through the attenuation of inflammatory cytokine genesis and the fine-tuning of inflammation-centric signaling cascades. Notwithstanding its merits, the innate low bioavailability of chlorogenic acid presents a therapeutic conundrum. To this end, this manuscript elucidates several delivery modalities, including liposomes, micelles, and nanoparticles, envisaged to ameliorate the therapeutic limitations of chlorogenic acid. These delivery systems bolster the stability and bioactivity of chlorogenic acid, prolong its pharmacodynamic span, and enhance its bioavailability.

28The current scientific literature offers a nascent understanding of the therapeutic efficacy and mechanistic intricacies of chlorogenic acid. While its profusion of anti-inflammatory targets, robust bioactivity, and ubiquitous presence in nature underscore its potential, several pivotal aspects warrant rigorous exploration. Notably, the majority of studies corroborating the bioactivity of chlorogenic acid are relegated to cellular and animal models; hence, the pressing need for expansive clinical trials to elucidate its therapeutic nuances further. Additionally, a discernible research void exists concerning the influence of physicochemical attributes on the delivery systems of chlorogenic acid, an avenue that necessitates rigorous academic attention to harness the full therapeutic potential of chlorogenic acid. Addressing these lacunae will pave the way for optimizing the anti-inflammatory, antioxidative, and potentially antineoplastic applications of chlorogenic acid. In summation, the research trajectory of chlorogenic acid is still in its incipient stages, and a plethora of investigative avenues beckons.